Details of the Drug

General Information of Drug (ID: DMXLE71)

Drug Name
SYL-040012
Synonyms SYL-0012; Beta 2 adrenoceptor-targeting siRNA (ocular hypertension), Sylentis
Indication
Disease Entry ICD 11 Status REF
Ocular hypertension 9C61.01 Phase 2 [1]
Drug Type
siRNA drug
Sequence
>Subunit 1
CUGGAUCACAUGCACAAUGTT
>Subunit 2
CAUUGUGCAUGUGAUCCAGTT
Cross-matching ID
TTD ID
D0Q8LL

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ADRB2 messenger RNA (ADRB2 mRNA) TTG8ZWP ADRB2_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Ocular hypertension
ICD Disease Classification 9C61.01
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
ADRB2 messenger RNA (ADRB2 mRNA) DTT ADRB2 1.10E-01 0.55 0.97
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02250612) SYL040012, Treatment for Open Angle Glaucoma. U.S. National Institutes of Health.
2 In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther. 2014 Jan;22(1):81-91.